E. Ehrnrooth

2.5k total citations
57 papers, 1.7k citations indexed

About

E. Ehrnrooth is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, E. Ehrnrooth has authored 57 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in E. Ehrnrooth's work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (13 papers) and HER2/EGFR in Cancer Research (11 papers). E. Ehrnrooth is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (13 papers) and HER2/EGFR in Cancer Research (11 papers). E. Ehrnrooth collaborates with scholars based in United States, Denmark and Spain. E. Ehrnrooth's co-authors include Hans von der Maase, Philip Rossen, Charlotte Gjørup Pedersen, Robert Zachariae, Anders Bonde Jensen, Ezra E.W. Cohen, Mai-Britt Zocca, Jérôme Fayette, Didier Cupissol and Paul M. Clément and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

E. Ehrnrooth

56 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Ehrnrooth United States	17	861	510	368	354	312	57	1.7k
Michael Hier Canada	26	778 0.9×	352 0.7×	404 1.1×	95 0.3×	650 2.1×	89	1.9k
Fengmin Zhao United States	29	2.0k 2.3×	752 1.5×	745 2.0×	402 1.1×	44 0.1×	77	3.0k
Janice Tsang Hong Kong	20	885 1.0×	222 0.4×	159 0.4×	91 0.3×	84 0.3×	39	1.3k
Geert H. Blijham Netherlands	21	989 1.1×	523 1.0×	372 1.0×	70 0.2×	409 1.3×	48	2.1k
Joseph J. Sacco United Kingdom	23	777 0.9×	221 0.4×	637 1.7×	422 1.2×	27 0.1×	88	1.9k
Matthew Burnell United Kingdom	25	1.1k 1.3×	500 1.0×	637 1.7×	113 0.3×	61 0.2×	66	3.3k
Kent Armeson United States	25	483 0.6×	391 0.8×	491 1.3×	102 0.3×	77 0.2×	67	1.5k
Ted A.W. Splinter Netherlands	28	1.2k 1.4×	1.4k 2.7×	362 1.0×	93 0.3×	104 0.3×	84	2.9k
Joshua Bauml United States	29	2.3k 2.6×	1.7k 3.3×	527 1.4×	375 1.1×	534 1.7×	140	3.3k
April Coan United States	26	1.3k 1.5×	655 1.3×	434 1.2×	559 1.6×	20 0.1×	38	3.0k

Countries citing papers authored by E. Ehrnrooth

Since Specialization

Citations

This map shows the geographic impact of E. Ehrnrooth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Ehrnrooth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Ehrnrooth more than expected).

Fields of papers citing papers by E. Ehrnrooth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Ehrnrooth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Ehrnrooth. The network helps show where E. Ehrnrooth may publish in the future.

Co-authorship network of co-authors of E. Ehrnrooth

This figure shows the co-authorship network connecting the top 25 collaborators of E. Ehrnrooth. A scholar is included among the top collaborators of E. Ehrnrooth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Ehrnrooth. E. Ehrnrooth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riess, Jonathan W., Ezra E.W. Cohen, James Spicer, et al.. (2023). 1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 34. S630–S630. 1 indexed citations

Lorentzen, Cathrine Lund, Evelina Martinenaite, Julie Westerlin Kjeldsen, et al.. (2022). Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial. Frontiers in Immunology. 13. 1023023–1023023. 36 indexed citations

Kjeldsen, Julie Westerlin, Cathrine Lund Lorentzen, Evelina Martinenaite, et al.. (2021). A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nature Medicine. 27(12). 2212–2223. 135 indexed citations

Kaae, Jeanette, Özcan Met, Signe Ledou Nielsen, et al.. (2021). Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study. Cancers. 13(4). 911–911. 10 indexed citations

Schüler, Martin, Luis Paz‐Ares, Lecia V. Sequist, et al.. (2019). First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 133. 10–19. 23 indexed citations

Provencio, Mariano, James Spicer, Pilar Garrido, et al.. (2019). P2.01-12 A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC. Journal of Thoracic Oncology. 14(10). S643–S643. 1 indexed citations

Sequist, Lecia V., Yi‐Long Wu, Martin Schüler, et al.. (2017). Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7. Annals of Oncology. 28. v482–v483. 10 indexed citations

Font, Albert, Francisco X. Real, Javier Puente, et al.. (2017). Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial. Annals of Oncology. 28. v326–v326. 2 indexed citations

Yang, James Chih‐Hsin, Glen Goss, Enriqueta Felip, et al.. (2017). LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung. Annals of Oncology. 28. ii37–ii37. 3 indexed citations

10.

Felip, Enriqueta, Vera Hirsh, Sanjay Popat, et al.. (2017). Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical Lung Cancer. 19(1). 74–83.e11. 25 indexed citations

11.

Goss, Glenwood, K.H. Lee, Enriqueta Felip, et al.. (2016). Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung. Annals of Oncology. 27. vi428–vi428. 1 indexed citations

12.

Clément, Paul M., Thomas Gauler, J.-P. Machiels, et al.. (2016). Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Annals of Oncology. 27(8). 1585–1593. 31 indexed citations

13.

Seiwert, Tanguy Y., Jérôme Fayette, Didier Cupissol, et al.. (2014). A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Annals of Oncology. 25(9). 1813–1820. 138 indexed citations

14.

Vermorken, Jan B., et al.. (2013). A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Annals of Oncology. 24(5). 1392–1400. 31 indexed citations

15.

Skak, Kresten, Henrik Søndergaard, Klaus Stensgaard Frederiksen, & E. Ehrnrooth. (2009). In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics. Cytokine. 48(3). 231–238. 4 indexed citations

16.

Folkesson, Joakim, Gerda Engholm, E. Ehrnrooth, et al.. (2009). Rectal cancer survival in the Nordic countries and Scotland. International Journal of Cancer. 125(10). 2406–2412. 21 indexed citations

17.

Gundgaard, Maria Gry, et al.. (2007). Third-line therapy for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 61(1). 1–13. 6 indexed citations

18.

Ehrnrooth, E., et al.. (2002). Increased Thymidylate Synthase mRNA Concentration in Blood Leukocytes following an Experimental Stressor. Psychotherapy and Psychosomatics. 71(2). 97–103. 5 indexed citations

19.

Ehrnrooth, E., Boe Sandahl Sørensen, Peter Meldgaard, et al.. (2000). A new quantitative RT–PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls. Clinica Chimica Acta. 290(2). 129–144. 3 indexed citations

20.

Horsman, Michael R., E. Ehrnrooth, Morten Ladekarl, & Jens Overgaard. (1998). The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. International Journal of Radiation Oncology*Biology*Physics. 42(4). 895–898. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact